oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort

Launched by THE UNIVERSITY OF HONG KONG · Dec 9, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a condition called ocular graft-versus-host disease (oGVHD) that can occur after a specific type of cancer treatment known as allogeneic hematopoietic stem cell transplantation (HSCT). oGVHD affects the eyes and can lead to serious problems like painful sores and vision loss. The goal of this study is to gather information from patients who received HSCT to better understand how common oGVHD is and how it progresses over time. This research is important because it will help develop better ways to prevent and manage this condition, which can significantly impact patients' quality of life.

To be eligible for this study, participants must be 18 years or older and have undergone allogeneic HSCT at Queen Mary Hospital within the last two years. They will attend follow-up visits where the research team will collect samples from their eyes and tears to study the condition further. Family members may also be invited to participate as controls, providing additional samples for comparison. Overall, this trial aims to improve our understanding of oGVHD and its effects on patients after their cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 or above
• • Underwent allogeneic HSCT in QMH in the two-year recruitment period
• Exclusion Criteria:
• • Underwent autologous HSCT
• • Patient unable to attend follow-up visits
• • Family Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.